Real-world effectiveness of SGLT2 inhibitors in patients with HF and ESKD: a multicenter cohort study
SGLT2i are significantly associated with reduced 1 year all-cause hospitalization, mortality, and acute pulmonary edema in HF and ESKD patients. These findings highlight the potential therapeutic role of SGLT2i in this high-risk population, warranting further clinical trials to confirm their efficacy and safety.
Authors
- Kuan-Jui Tseng
- Jheng-Yan Wu
- Chia-Li Kao
- Tsung Yu
- Yu-Min Lin
- Kuo-Chuan Hung
Institutions
- E-Da Hospital (TW)
- Chi Mei Medical Center (TW)
- National Cheng Kung University (TW)
- I-Shou University (TW)
Publication Details
- Journal
- Frontiers in Cardiovascular Medicine
- Published
- 2026-01-16
- DOI
- https://doi.org/10.3389/fcvm.2026.1652863
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00